|Project Title||Principal Investigator||Institution|
|Validation study of atypical dynamic pupillary light reflex as a biomarker for autism||Yao, Gang; Miles, Judith; Christ, Shawn||University of Missouri|
|The ontogeny of social visual engagement in infants at risk for autism||Klin, Ami||Yale University|
|The emergence of emotion regulation in children at-risk for autism spectrum disorder||Ekas, Naomi||University of Miami|
|Temporal coordination of social communicative behaviors in infant siblings of children with autism||Parlade, Meaghan||University of Pittsburgh|
|Temperament, emotional expression, and emotional self-regulation in relation to later ASD diagnosis||Wozniak, Robert||Bryn Mawr College|
|Supplement to NIH ACE Network grant: "A longitudinal MRI study of infants at risk for autism"||Piven, Joseph||University of North Carolina at Chapel Hill|
|Studying the biology and behavior of autism at 1-year: The Well-Baby Check-Up approach||Pierce, Karen||University of California, San Diego|
|Signatures of gene expression in autism spectrum disorders||Kunkel, Louis||Children's Hospital Boston|
|RNA expression studies in autism spectrum disorders||Kunkel, Louis||Children's Hospital Boston|
|Pupil size and circadian salivary variations in autism spectrum disorder||Colombo, John||University of Kansas|
|Prospective study of infants at high risk for autism||Chawarska, Katarzyna||Yale University|
|Placental vascular tree as biomarker of autism/ASD risk||Salafia, Carolyn||Research Foundation for Mental Hygiene, Inc.|
|Physical and clinical infrastructure for research on infants-at-risk for autism at Yale||Klin, Ami||Yale University|
|Oxytocin biology and the social deficits of autism spectrum disorders||Parker, Karen||Stanford University|
|Observational and electrophysiological assessments of temperament in infants at risk for autism spectrum disorders||Burner, Karen||University of Washington|
|Neurophysiological investigation of language acquisition in infants at risk for ASD||Seery, Anne||Boston University|
|Neurophysiological indices of risk and outcome in autism||Webb, Sara||University of Washington|
|Neurobehavioral research on infants at risk for SLI and autism||Tager-Flusberg, Helen; Nelson, Charles||Boston University Medical Campus|
|Multiplexed suspension arrays to investigate newborn and childhood blood samples for potential immune biomarkers of autism||Vogt, Robert||Centers for Disease Control and Prevention (CDC)|
|Model diagnostic lab for infants at risk for autism||Klin, Ami||Yale University|
|Misregulation of BDNF in autism spectrum disorders||Hempstead, Barbara||Weill Cornell Medical College|
|Metabolic biomarkers of autism: Predictive potential and genetic susceptibility||James, Sandra||Arkansas Children's Hospital Research Institute|
|Infants at risk of autism: A longitudinal study||Ozonoff, Sally||University of California, Davis|
|Identifying gastrointestinal (GI) conditions in children with autism spectrum disorders (ASD)||Winter, Harland||Harvard Medical School|
|Identification of lipid biomarkers for autism||Kang, Jing||Massachusetts General Hospital|
|IACC Strategic Plan Objective||2008||2009||2010||2011||2012||Total|
|Identify behavioral and biological markers that separately, or in combination, accurately identify, before age 2, one or more subtypes of children at risk for developing ASD, and evaluate whether these risk markers or profiles can improve early identification through heightened developmental monitoring and screening by 2014.
IACC Recommended Budget: $33,300,000 over 5 years
|1.L.A. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.
Progress: More than 40 projects have been supported in this area, but most projects are still in the discovery phase. Identifying reliable early biomarkers has been challenging, but some progress has been made. More work is needed to achieve the full intent of the objective.
Remaining Gaps, Needs, and Opportunities: Remaining research needs include continued discovery of biomarkers, linking biomarkers to treatment response, validation of biomarkers discovered in high risk populations for applicability in the general population, and evaluation of whether these biomarkers translate to improvement in screening and diagnosis real-world settings. There is also a need for biomarkers that are cost-effective.